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Abstract
Background
For the treatment of depressive disorders, the framework of collaborative care has been
recommended, which showed improved outcomes in the primary care sector. Yet, an earlier
literature review did not find sufficient evidence to draw robust conclusions on the cost-ef-
fectiveness of collaborative care.
Purpose
To systematically review studies on the cost-effectiveness of collaborative care, compared
with usual care for the treatment of patients with depressive disorders in primary care.
Methods
A systematic literature search in major databases was conducted. Risk of bias was as-
sessed using the Cochrane Collaboration’s tool. Methodological quality of the articles was
assessed using the Consensus on Health Economic Criteria (CHEC) list. To ensure compa-
rability across studies, cost data were inflated to the year 2012 using country-specific gross
domestic product inflation rates, and were adjusted to international dollars using purchasing
power parities (PPP).
Results
In total, 19 cost-effectiveness analyses were reviewed. The included studies had sample
sizes between n = 65 to n = 1,801, and time horizons between six to 24 months. Between
42% and 89% of the CHEC quality criteria were fulfilled, and in only one study no risk of bias
was identified. A societal perspective was used by five studies. Incremental costs per de-
pression-free day ranged from dominance to US$PPP 64.89, and incremental costs per
QALY from dominance to US$PPP 874,562.
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Conclusion
Despite our review improved the comparability of study results, cost-effectiveness of collab-
orative care compared with usual care for the treatment of patients with depressive disor-
ders in primary care is ambiguous depending on willingness to pay. A still considerable
uncertainty, due to inconsistent methodological quality and results among included studies,
suggests further cost-effectiveness analyses using QALYs as effect measures and a time
horizon of at least 1 year.
Introduction
In 2010, major depressive disorder (MDD) accounted for 2.5% of the world’s total global bur-
den of disease expressed in disability-adjusted life years (DALY) and ranked second with re-
spect to years lived with disabilities (YLD) [1]. In Europe, lifetime prevalence estimations of
MDD range from 11.6% to 17.1% with comorbidities being highly prevalent [2–5].
Mean annual costs per patient with MDD in Europe have been estimated at €3,034, of
which €1,251 were due to (non-)medical treatment (direct costs) and €1,782 were due to re-
duced productivity (indirect costs) [6]. A review of cost-of-illness studies of depression esti-
mated the average annual direct excess costs for a depressed individual at US$1,000 to US
$2,500 [7].
MDD is associated with one or more episodes of depressed mood or loss of interest in plea-
sure in nearly all activities over a period of at least two weeks [8]. MDD requires treatment be-
cause otherwise substantial psychosocial problems may occur [9]. Patients with sub-threshold
depressive symptoms or mild depression are advised by clinical practice guidelines to be treated
with low-intensity psychological interventions and group cognitive behavioral therapy. Pa-
tients with moderate to severe depression are advised to be treated either with an antidepres-
sant medication or high-intensity psychological interventions alone, or with a combination of
both [10, 11]. The clinical practice guideline of the English National Institute for Health and
Clinical Excellence (NICE) [10] also advises to use the framework of a stepped-care model to
organize the provision of services, and support patients, carers and physicians in identifying
and accessing the most effective interventions. The steps of such a model should consist of psy-
choeducation, active monitoring, medication and psychosocial interventions.
One way to use the framework of stepped-care and to coordinate care is represented by the
collaborative care approach, which is particularly recommended for patients with persistent
sub-threshold depressive symptoms or mild to moderate depression with inadequate response
to initial interventions, and moderate to severe depression [10]. Collaborative care is a multi-
faceted intervention that targets patient, physician and structural aspects of care. Treating phy-
sicians should be able to coordinate care, guide treatment based on relevant information and
synchronize decisions and treatments by ongoing contact with other professionals [12]. Collab-
orative care was initially developed to improve treatment of depression and short-term clinical
outcomes [13]. According to Barkil-Oteo [14], collaborative care improves care for depression
in different settings and populations, especially in the primary care sector, which plays a central
role in the mental health system and the treatment of depression. Collaborative care for pa-
tients with depression was found to be effective in terms of depression outcomes, antidepres-
sant use and quality of life [15–17].
In order to compare the costs and outcomes of collaborative care with usual care or an alter-
native intervention, cost-effectiveness analyses (CEAs) are applied. In CEAs, a ratio between
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the differences in costs and the differences in effects of alternative treatments is calculated. One
earlier literature review published by van Steenbergen-Weijenburg et al. [18] in 2009 systemati-
cally examined cost-effectiveness studies of (stepped) collaborative care for patients with major
depressive disorders in the primary care setting. The economic evidence was not sufficient to
draw robust conclusions on the cost-effectiveness of collaborative care for patients with depres-
sive disorders. To our knowledge, no more recent systematic review on this topic exists, al-
though several new cost-effectiveness trials on collaborative care for patients with depressive
disorders have been published in the last years, such as from the PROMODE study [19], the
MDDP study [20] or the TEAM study [21, 22].
The aim of this paper is to systematically review studies on the cost-effectiveness of
(stepped) collaborative care compared with usual care for the treatment of patients with de-
pressive disorders in primary care. It provides an update and extension of the literature review
by van Steenbergen-Weijenburg et al. [18] by adding recently published studies to the quantita-
tive analysis, improving the comparability of studies by means of inflating and adjusting costs
to international dollars, and assessing the quality and risk of bias of included studies.
Materials and Methods
Search methods
A systematic literature search was conducted in PubMed, PsychINFO, Embase, Cinahl, Econ-
Lit, the Cochrane Library and NHS EED in March 2014 and was updated in February 2015
using a validated rapid review method to minimize time lag of this review [23]. The following
search term was used: (depressive disorder OR depression) AND (collaborative care OR disease
management OR stepped care) AND (cost-benefit analysis OR cost-effectiveness OR cost-utili-
ty OR economic evaluation). Subject headings were additionally used, when applicable. Fur-
thermore, references of studies included in qualitative synthesis and of reviews excluded
during eligibility assessment were screened for further eligible studies. The literature search
was not limited to any publication year. The studies from the previous review [18] were incor-
porated in the current review. Articles without abstracts were not included in the data analysis.
Inclusion of studies
Title and abstract of all articles were independently screened for relevance by two authors (TG
and AW). Articles that were deemed relevant were considered in full text. On disagreement,
consensus was reached by involving a third author (CB). Full texts of all potentially relevant
studies were assessed and included, when
• a cost-effectiveness analysis was presented
• the intervention was (stepped) collaborative care, and
• the study population consisted of patients with depressive disorders.
Articles were excluded if they were protocols, letters, editorials, conference abstracts, case
reports, reviews, if the study objectives were other than evaluation of cost-effectiveness of col-
laborative care, if studies only described decision-analytic models, or if the full text was not
available in English or German.
Comorbidity of a depressive disorder and other diseases was accepted if the focus of collabo-
rative care was on depressive disorder. The intervention of the studies had to comply with the
definition of (stepped) collaborative care for the treatment of a depressive disorder in primary
care provided by van Steenbergen-Weijenburg et al. [18] which closely corresponds to another
widely used definition of system level depression management interventions in primary care
Cost-Effectiveness of Collaborative Care
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[24]. Accordingly, programs were defined as collaborative care if treatment complied with at
least three of the following four criteria [18]:
1. “Within [(stepped)] collaborative care the role of care manager is introduced to assist and
manage the patient by providing structured and systematic interventions.
2. A network is formed around the patient with at least two (. . .) professionals [(e.g. primary
care physician, care manager, and/or consultant psychiatrist)] (. . .) [13, 25].
3. Process and outcome of treatment is being monitored and in case of insufficient improve-
ment, treatment may be changed according to the principles of stepped care [26].
4. Evidence-based treatment is provided [(e.g. on the basis of a clinical practice guideline [10,
11])] [26].”
Quality assessment and data abstraction
The risk of bias in studies included in this review was assessed using the Cochrane Collabora-
tion’s tool [27] addressing seven specific domains (sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting and ‘other issues’). For the economic evaluation as-
pects of the articles, the Consensus on Health Economic Criteria (CHEC) list for economic
evaluations [28] was used as a quality criteria list. The CHEC-list addresses 19 categories as-
sessing methodological quality of economic evaluations [28]. If necessary, information was re-
trieved from related studies or protocols when they were stated as source. Two authors (TG
and AW) independently assessed the risk of bias of the studies as well as the methodological
quality of the economic evaluations. Discussion or third opinion (CB) was used in case of dis-
agreement. Independently from the methodological quality and the risk of bias of each study,
all available evidence was used for analysis to avoid loss of information. Risk of bias data was
processed graphically with Review Manager 5.3 [29].
All abstracted data (e.g. perspectives, effect measurements, cost measurements, incremental
cost-effectiveness or cost-utility ratios) from each selected study was entered into spreadsheets.
Analysis of included studies
As summary measures, incremental cost-effectiveness ratios (ICERs) in terms of incremental
costs per depression-free day (DFD), per quality-adjusted life years (QALYs) or per other out-
comes were reported.
To ensure comparability across studies, cost data were inflated to the year 2012, using coun-
try-specific gross domestic product (GDP) inflation rates [30], and were adjusted to interna-
tional dollars using GDP purchasing power parities (US$PPP) [30]. If no reference year for
cost valuation was given, the middle of the follow-up period was used as reference for inflation.
If the follow-up period was not reported, the publication year was used as reference. Cost mea-
surements were classified into two different perspectives of economic evaluations according to
the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) [31]: the
health-care system perspective or the societal perspective, respectively. Incremental cost-effec-
tiveness ratios were not pooled since there are no accepted methods of pooling [32].
Cost-Effectiveness of Collaborative Care
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Results
Study selection
In total, 736 articles were identified. Based on title and abstract screening for relevance, 197 du-
plicates and 487 non-relevant articles were removed. From the remaining 52 potentially rele-
vant articles, full texts were retrieved and examined for relevance. Thirty-five were rejected (15
reviews, 2 conference abstracts, 7 no collaborative care, 10 no cost-effectiveness analysis, 1 only
subgroup analysis). An update of the systematic literature search identified two additional arti-
cles. Finally, 19 studies were included in the review [33–51]. Through the search, all eight stud-
ies included in the literature review by van Steenbergen-Weijenburg et al. [18] were identified.
A flow chart of the selection process is presented in Fig 1.
Study characteristics
The general characteristics of the included CEA are presented in Table 1. The included studies
originated from the United States (n = 12), the Netherlands (n = 4), Chile (n = 1), Spain (n = 1)
and the United Kingdom (n = 1). The earliest study was published in 1998 [49] and the most
recent were published in 2014 [33, 50, 51]. All but three studies were multicenter trials con-
ducted in primary care clinics (n = 10), primary care practices (n = 7), residential homes
(n = 1) or an occupational health care setting (n = 1). The mean number of centers was 22,
ranging from one to 89 centers.
Fig 1. Flow chart of the selection process based on the PRISMA Statement [75].
doi:10.1371/journal.pone.0123078.g001
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The sample size varied from N = 65 in one trial with a single center to N = 1,801 in a trial
with 18 centers (mean sample size N = 392). All studies focused on patients with depressive
disorders alone, with depressive symptoms or at risk of depressive disorders. Three studies
only included patients with comorbid diabetes [37, 44], or both, diabetes and coronary heart
disease [38]. One study only included patients with depressive symptoms following coronary
artery bypass graft [51]. The mean age of the patients varied from 42 years to 84 years (overall
Table 1. General characteristics of the included studies.
Study Population Sample size
(IG/CG)
Mean age IG/
CG (SD)
% Female
IG/CG
Setting (n) Country
Aragonès et al. 2014
[33, 76, 77]
Patients with major depression 338 (166/126) 47.5 (15.5) /
47.8 (14.9)
81.0 / 77.2 PCC (20) Spain
Araya et al. 2006 [34] Female patients aged 18–70 with major
depression
240 (96/95) 44.1 (12.1) /
42.0 (13.7)
100.0 PCC (3) Chile
Bosmans et al. 2014
[35]
Elderly residential home residents at risk of
major depression and/or anxiety disorder
185 (93/92) 84.0 (6.7) /
84.0 (6.4)
72.0 / 74.0 Residential homes NL
Donohue et al. 2014 [51,
78, 79]
Post-CABG patients with depressive
symptoms
189 (90/99) 66.9 (9.0) /
67.1 (11.5)
36.0 / 41.0 PCP USA
Goorden et al. 2013 [36,
80]
Sick-listed employees with major
depression
126 (65/61) 41.9 (11.4) /
43.4 (11.4)
53.8 / 54.1 Occupational
Health Care
NL
Green et al. 2014 [50,
81, 82]
Patients with major depression 581 (276/305) 45.0 (13.2) /
44.5 (13.4)
73.2 / 70.8 PCP (49) UK
Hay et al. 2012 [20, 37] Low income patients with major depression
and diabetes
387 (193/194) Not given 85.5 / 79.8 PCC (2) USA
Katon et al. 2012 [38,
83]
Patients with major depression and
diabetes and/or CHD
214 (106/108) 57.4 (10.5) /
56.3 (12.1)
48.0 / 56.0 PCC (14) USA
Katon et al. 2005 [39, 84,
85]
Patients aged 60 with major depression
and/or dysthymia
1801 (906/
895)
71.0 (7.4) /
71.4 (7.5)
65.0 / 64.0 PCC (18) USA
Liu et al. 2003 [40] Patients with major depression and/or
dysthymia
354 (168/186) 57.8 (13.5) /
56.6 (14.2)
95.0 / 96.0 PCC (1) USA
Pyne et al. 2010 [21, 22,
41]
Patients with major depression 320 (141/179) 58.8 (11.4) /
60.0 (11.7)
5.0 / 11.0 PCP (89) USA
Rost et al. 2005 [42, 86,
87]
Patients with major depression 211 (115/96) 43.1 (14.8) 84.4 PCP (12) USA
Schoenbaum et al. 2001
[43, 88, 89]
Patients with major depression 1356 (424
+489/ 443)
44.5 (15.5) /
42.2 (13.9)
71.6 / 69.0 PCP (48) USA
Simon et al. 2007 [44,
90, 91]
Patients with major depression and
diabetes
329 (165/164) 58.0 (12.0) /
57.0 (12.0)
35.0 / 34.0 PCC (9) USA
Simon, Katon et al. 2001
[45, 92]
Patients with depressive symptoms 228 (110/109) 47.0 (14.0) 74.0 PCC (4) USA
Simon, Manning et al.
2001 [46]
Patients with major depression 407 (218/189) 45.6 (8.6) /
45.4 (9.6)
77.0 / 78.0 PCC (7) USA
van der Weele et al.
2012 [47]
Patients aged 75 with untreated
depressive symptoms
239 (121/118) 80.0 / 80.0 70.0 / 75.0 PCP (67) NL
van't Veer-Tazelaar
et al. 2010 [48, 93]
Patients aged 75 at risk of major
depression and anxiety disorder
170 (86/84) 81.8 (3.8) /
81.1 (3.5)
69.8 / 77.4 PCP (33) NL
Von Korff et al. 1998
[13, 49, 52]*
Patients with major depression 91 (49/42) 43.2 (15.4) /
42.3 (12.7)
77.5 / 88.1 PCC (1) USA
65 (31/34) 43.1 (9.3) /
44.8 (15.9)
77.4 / 73.5
CABG = Coronary Artery Bypass Graft, CHD = Coronary Heart Disease, IG = Intervention Group, CG = Control Group, PCC = Primary Care Clinic,
PCP = Primary Care Practice, NL = the Netherlands, UK = United Kingdom
*Analysis was based on two RCT
doi:10.1371/journal.pone.0123078.t001
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mean age 56 years). Four studies only included aged patients with an overall mean age of 79
years [35, 39, 47, 48]. The overall mean percentage of included female patients was 68%, rang-
ing from 8% in the study by Pyne et al. [41], where the setting was a veteran population, to
100% in the study by Araya et al. [34], where only women were included on purpose.
A societal perspective was used by five studies [35, 36, 43, 47, 48] and eleven studies used a
health care perspective [34, 36–41, 44, 45, 49–51]. Both, a health care perspective and a societal
perspective, was used by three studies [33, 42, 46].
All studies indicated that a care manager assisted and managed the patient by providing
structured and systematic interventions. In ten studies, the care management was implemented
by nurses/health care professionals solely [33, 38, 40–45, 51] or, in addition, social workers
[34] or psychologists [39, 50], respectively. Physicians were care managers in three studies [35–
37].
In all studies, a network was formed around the patient comprising at least two profession-
als [34–36, 43, 45, 46, 49]. In ten studies, the network was composed of three professionals [33,
37–40, 42, 47, 48, 50, 51] and in two studies, the network was composed of four to five different
professionals [41, 44]. Professionals routinely associated with the network were mainly primary
care physicians [33, 35–47, 49–51], specialized nurses [33–35, 38, 39, 41–44, 47, 48, 51] and
psychiatrists [38–40, 44, 45, 49, 51]. Other professionals associated with the network were psy-
chologists [39, 40, 44, 50], social workers [34, 37, 40] and pharmacologists [41].
Monitoring was an element of collaborative care in all but two studies [35, 47]. Treatment
progress and response was monitored in nine studies [34, 36, 38–40, 46, 49–51] and medication
or treatment adherence in twelve studies [33, 34, 40–46, 49–51]. Symptoms were being moni-
tored in six studies [34, 37, 41–43, 48] and adverse effects were being identified through moni-
toring in three studies [33, 41, 46]. Treatment of patients was adapted according to the
principles of stepped care in eleven studies [34–37, 39–41, 44, 47, 48, 51].
Evidence-based treatment was provided in all studies. The majority of studies provided pa-
tients in the collaborative care group with antidepressant pharmacotherapy [33, 34, 36, 37, 39–
46, 49–51]. Further evidence-based treatments used in the studies were psychoeducation [33,
34, 37–40, 42, 43, 45, 46, 49, 51], psychotherapy (e.g. cognitive behavior therapy) [35, 36, 40,
42–45, 47–50], counseling [34, 35, 40, 41, 44–47, 49, 51] and problem-solving treatment [36–
39, 44, 48, 49].
All but two studies used patients with usual care as control group. One study presented pa-
tients in the control group with depression educational pamphlets and community service re-
source lists additionally to usual care [37]. The control group patients in another study were
advised to consult with their primary physician to receive care for depression beyond usual
care [38].
Ten studies reported cost adjustment by usage of reference unit prices for a certain year
[35–37, 40–43, 48, 50, 51] and three studies stated that there was no need to discount cost data
because of a short follow-up [33, 34, 47].
Quality and risk of bias assessment
Between 42% and 89% of the CHEC-list criteria [28] were fulfilled by the studies. The mean
quality criteria fulfillment was 69%. Four studies [33, 35, 36, 47] were able to address almost all
methodological quality criteria from the CHEC-list, two studies [45, 49] failed to address the
majority of these quality criteria. Results of quality assessment based on the CHEC-list are pre-
sented in S1 Table.
No risk of bias was identified in the study by Aragonés et al. [33]. High risk of attrition bias
was identified in two studies [35, 39]. Other biases, such as a too small sample size, a high
Cost-Effectiveness of Collaborative Care
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proportion of missing cost data, randomization imbalances or crossover, appeared in nine
studies [35–37, 39, 43–45, 49, 51]. Results for the authors' judgments on risk of bias items for
each included study and for each risk of bias item as percentages across all included studies are
presented in S1 and S2 Figs.
Effects
Depression-free days. More than half of the studies reported incremental DFDs [34, 38–
40, 44–46] or, both, DFDs and QALYs [33, 42, 51]. The studies which reported DFDs as their
primary effect measure calculated them using the Hamilton Rating Scale for Depression
(HDRS) [34, 46, 51], the 20-item Hopkins Symptom Checklist Depression Scale (HSCL-20)
[39], the Patient Health Questionnaire (PHQ-9) [33], or the Symptom Checklist-90 (SCL-90)
[38, 40, 44, 46]. The study by Rost et al. [42] used directly reported depression impairment-free
days. For a follow-up period of less than twelve months, the lowest/highest reported effects
were 14.6 [40] and 50 [34] incremental DFDs, respectively. For a follow-up of twelve months
(24 months) the lowest/highest reported effects were 20 [51] and 47.4 [46] (48 [44] and 107
[39]) incremental DFDs, respectively. In two studies with DFDs as effect measure, the incre-
mental effect was not statistically significant [40, 51]. The main findings concerning the cost-
effectiveness of collaborative care vs. usual care of the included studies are summarized in
Table 2.
QALYs. QALYs were reported by more than half of the studies [33, 35–38, 41–43, 47, 51].
Both [47, 50] or either the EQ-5D [33, 36, 41] and the Short Form Health Survey (SF-12/SF-
6D) [33, 37, 43, 51] were used to calculate QALYs. Two studies generated QALYs based on age,
gender plus clinical measures [38] and DFDs [42], respectively, using a regression model. For a
follow-up of ten to twelve months (18 to 24 months), the lowest positive effect was 0.008 [47]
(0.0115 [43]) additional QALYs and the highest effect was 0.05 [51] (0.335 [38]). Two studies
found incremental QALYs for usual care compared to collaborative care of 0.05 [36] and 0.021
[47], respectively. In four studies with QALYs as effect measure, the incremental effect was not
statistically significant [35, 36, 49, 50].
Other effects. One study, which examined the preventive effect of stepped collaborative
care for people at risk for depression and anxiety disorders, reported a probability of a depres-
sion/anxiety-free year of 0.88 in the collaborative care group and of 0.76 in the usual care
group, respectively, leading on to an incremental effectiveness of 0.12. [48]. In another study,
which examined the improvement in major depression status through collaborative care based
on two clinical trials, 30.6% [13] and 28.1% [52], respectively, more patients in the collaborative
care group improved compared to patients with usual care [49]. However, no statistical signifi-
cance testing was reported for incremental effectiveness.
Costs
Direct costs. All but two studies included medication and outpatient care costs. The stud-
ies of Green et al. [50] and Donohue et al. [51] excluded medication costs due to difficulties in
data collection. Some studies also considered inpatient care costs [33, 35, 37–39, 41, 45, 46, 50,
51] and non-medical and paramedical costs [36, 47, 48, 50]. Of all studies, 76% reported posi-
tive incremental direct costs of collaborative care with a range between US$PPP 46 [34] to
3,761 [41]. Negative incremental direct costs were reported with a range between US$PPP
−529 [51] to −982 [44] in favor of the collaborative care group. However, twelve studies either
reported non-significant incremental costs [35, 38–40, 43, 44, 47, 48, 50, 51] or no statistical
significance testing was reported for incremental costs [36, 49], respectively. A summary of di-
rect cost elements and mean costs of the studies is given in S2 Table.
Cost-Effectiveness of Collaborative Care
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Table 2. Cost-effectiveness of collaborative care vs. usual care.
Study Follow up
in
months
Perspective Classiﬁcation Reference
year
Incremental
Effects§ (95% CI)
Converted
incremental Costs
per US$PPP (95%
CI)
Converted ICER in
US$PPP (95% CI)
Effect measure: Depression-free days
Aragonès et al.
2014 [33, 76, 77]
12 HCP PHQ-9 2009* 40.1† 260.99 (SD 76.01)‡ 6.51
SP 225.12 (SD 222.23) 5.62
Araya et al. 2006
[34]
6 HCP HDRS 2004** 50† 47.29 (30.78 to
67.68)†
0.94 (0.56 to 1.49)
Katon et al. 2012
[38, 83]
24 HCP SCL-90 2009* 114 (79 to 149)† −623.51 (−3,590,95
to 3,020.97)
Dominant (−31.24 to
20.12)
Donohue et al.
2014 [51, 78, 79]
12 HCP HDRS 2004 20 (-8 to 48) −528.70 Dominant (−75.36 to
−36.50)
Katon et al. 2005
[39, 84, 85]
24 HCP HSCL-20 2005*** 107 (86 to 128)† 788.43 (1,520.95 to
3,097.82)
56.59 (−17.30 to
131.19)
Liu et al. 2003 [40] 9 HCP SCL-90 2000 14.6 (−0.5 to 29.6) 216.66 (−2,373.02
to 3,144.80)
2.56 (−325.63 to
510.24)
Simon et al. 2007
[44, 90, 91]
24 HCP SCL-90 2007*** 48 (23 to 73)† −338.63 (−1,086.00
to 408.73)
Dominant (−18.98 to
7.76)
Simon, Katon
et al. 2001 [45, 92]
6 HCP SCL-90 2001*** 16.7 (1.3 to 31)† 731.44 (619.97 to
2,077.85)†
37.64 (-64.79 to
485.38)
Simon, Manning
et al. 2001 [46]
12 HCP HDRS 2001*** 47.4 (26.6 to 68.2)† 2,472.38 (1,062.09
to 3,144.80)†
51.78 (20.09 to
101.49)
SP 3,099.86 (1,102.17
to 5,182.72)†
64.89 (21.76 to
135.86)
Effect measure: QALY
Aragonès et al.
2014 [33, 76, 77]
12 HCP SF-6D 2009* 0.045 (SD 0.019)† 260.99 (SD 76.01)‡ 5,800
SP 225.12 (SD 222.23) 5,003
Bosmans et al.
2014 [35]
10 SP EQ-5D 2008 0.03 (−0.03 to 0.09) 1,083.11 (−766.45
to 3,127.83)
34,755
Goorden et al.
2013 [36, 80]
12 SP EQ-5D 2009 −0.05 (−0.11 to
0.00)
−915.51 18,838 (per QALY
gained by usual
care)
Donohue et al.
2014 [51, 78, 79]
12 HCP SF-6D 2004 0.05 (0.02 to 0.08)† −528.70 Dominant (−14,059
to −9,229)
Green et al. 2014
[50, 81, 82]
12 HCP EQ-5D 2011 0.019 (−0.019 to
0.06)
391.04 (−293.19 to
1,279.82)
20,580
SF-6D 0.0168 (0.000 to
0.032)
23,276
Hay et al. 2012
[20, 37]
18 HCP SF-12 2009 0.13‡ 540.58† 4,254
Katon et al. 2012
[38, 83]
24 HCP Regression
model¶
2009* 0.335 (−0.18 to
0.58)
−623.51 (−3,590.95
to 2,154.99)
Dominant (−3,021 to
3,021)
Pyne et al. 2010
[21, 22, 41]
12 HCP EQ-5D 2005 0.018† 1,854.66‡ 153,299
Rost et al. 2005
[42, 86, 87]
24 SP Regression model
(based on DFDs)
2000 0.049† 898.70 (816.65 to
980.75)‡
18,341
Schoenbaum
et al. 2001 [43, 88,
89]
24 SP SF-12 1998 0.0115 (−0.004 to
0.027)
557.20 (−621.03 to
1,736.77)
48,495 (QI-meds)
0.0226 (0.008 to
0.038)†
644.97 (−522.63 to
1,736.77)
28,562 (QI-therapy)
0.0173 (0.004 to
0.030)†
603.75 (−405.60 to
1,614.42)
34,899 (pooled)
(Continued)
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The mean intervention cost of all studies ranged between US$PPP 90 [33] to 1,269 [38], ex-
cept for the study by Araya et al. [34] which reported intervention costs of only US$PPP 19.
The intervention components ranged from only additional individual consultations from care
managers [33, 36, 46, 47, 49] to complex (stepped) collaborative care interventions [34, 35, 38,
39, 43, 48, 51]. A detailed description of the intervention costs is given in S3 Table.
Indirect costs. Aragonès et al. [33] reported mean indirect costs of temporary disability
leave from work amounting to US$PPP 899 (930) in the collaborative care group (usual care
group). The mean productivity costs as reported by Goorden et al. [36] were US$PPP 14,920
(17,158). These costs consisted of US$PPP 1,988 (2,441) for absenteeism and US$PPP 13,065
(15,947) for presenteeism, respectively [36]. Three studies interpreted patient time and travel
costs as indirect costs [36, 37, 41], and one of these studies only indicated that they ascertained
indirect costs for their economic evaluation but did not report them separately [37].
Table 2. (Continued)
Study Follow up
in
months
Perspective Classiﬁcation Reference
year
Incremental
Effects§ (95% CI)
Converted
incremental Costs
per US$PPP (95%
CI)
Converted ICER in
US$PPP (95% CI)
van der Weele
et al. 2012 [47]
12 SP SF-12 2001* 0.008 6,996.50 874,562 (age 75–80)
0.02 −859.59 Dominant (age 80)
EQ-5D 2001* −0.021 6,996.50 Dominated (age 75–
80)
0.044 −859.59 Dominant (age 80)
Other effect measures
van't Veer-
Tazelaar et al.
2010 [48, 93]
12 SP Depression-/
anxiety-free year
2007 0.12 (0.01 to 0.24)†
probability for a
beneﬁcial outcome
702.87 5,677 (−1,175 to
35,774) per
depression/anxiety-
free year
Von Korff et al.
1998 [13, 49, 52]&
7 HCP Successfully
treated case
(SCL-90)
1995*** 30.6% successfully
treated cases of
major depression
677.64 2,215 per
successfully treated
case of major
depression
1996*** 28.1% successfully
treated cases of
major depression
497.39 1,284 per
successfully treated
case of major
depression
HCP = Health Care Perspective; SP = Societal Perspective; DFD = Depression-free day; QALY = Quality-adjusted life year; PHQ-9 = Patient Health
Questionnaire; HDRS = Hamilton Rating Scale for Depression; SCL-90 = Symptom Checklist-90; HSCL-20 = 20-item Hopkins Symptom Checklist
Depression Scale; SF-12 = 12-Item Short Form Health Survey; CLP = Chilean Pesos; ICER = Incremental Cost-Effectiveness Ratio; QI-meds = quality
improvement—medical management; QI-therapy = quality improvement—psychotherapy
&Analysis was based on two RCT
§Based on follow up in months
¶QALYs were estimated based on age, sex, microalbuminuria, HbA1c, LDL-C and systolic blood pressure levels
*Based on the middle of the follow up period
**Based on the year of article receipt by journal
***Based on the publication year
†signiﬁcant with p<0.05
‡signiﬁcant with p<0.00
doi:10.1371/journal.pone.0123078.t002
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Cost-effectiveness
Cost-effectiveness per depression-free day. All but three studies with DFDs as effect mea-
sure reported that collaborative care is more effective in terms of additional DFD, but also
more expensive [33, 34, 39, 40, 45, 46]. From a health care perspective, ICERs ranged from
dominance [38, 44, 51] to US$PPP 56.59 [39] per additional DFD. From a societal perspective,
the ICERs ranged from US$PPP 5.62 [33] to 64.89 [46] per additional DFD. The directions of
the differences in costs and depression free days (and QALYs) are summarized in a cost-effec-
tiveness plane (Fig 2).
Cost-effectiveness per QALY. The majority of studies with QALYs as effect measure re-
ported that collaborative care is more effective in terms of additional QALYs, but also more ex-
pensive [33, 35–37, 41–43, 47, 50] (Fig 2). From a health care perspective, ICERs ranged from
dominance [38, 51] to US$PPP 153,299 [41] per additional QALY. From a societal perspective,
ICERs ranged from dominance [47] to US$PPP 874,562 [47] per additional QALY. The study
by van der Weele et al. [47] reported that collaborative care dominated usual care in patients
aged>80 years, but was dominated by usual care in patients aged 75 to 80 years. The study by
Goorden et al. [36] found higher costs and higher effects for usual care compared to collabora-
tive care, with an ICER of US$PPP 18,838 per additional QALY.
Cost-effectiveness per other outcome. One study of stepped collaborative care for people
aged75 at risk for depression and anxiety disorders indicated that collaborative care is more
effective in terms of preventing depression/anxiety disorders but also more expensive com-
pared to usual care [48]. The ICER was US$PPP 5,677 per depression/anxiety-free year. Anoth-
er study indicated that collaborative care for depressed primary care patients is more effective
Fig 2. Cost effectiveness plane for studies with costs per DFD/QALY. In capitals: studies with a societal
perspective, in italics: studies with costs per DFD, in bold: studies with costs per DFD and QALY, APatients
aged 75–80, effectiveness measurement instrument EQ-5D; BPatients aged 75–80, effectiveness
measurement instrument SF-12, CPatients aged80.
doi:10.1371/journal.pone.0123078.g002
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in terms of successfully treated cases but also more expensive compared to usual care [49].
Based on two clinical trials, the ICER was US$PPP 2,215 (1,284) per case successfully treated.
Neither of these two studies reported, both, a significant incremental effect and significant
incremental costs.
Discussion
This study reports a systematic review of cost-effectiveness analyses of (stepped) collaborative
care compared with usual care for the treatment of patients with depressive disorders in prima-
ry care. In 13 of the 19 included studies, collaborative care was associated with better effects
and higher costs (Fig 2). Across the studies showing a higher effectiveness in terms of addition-
al QALYs, collaborative care was associated with ICERs ranging from dominance to US$PPP
153,299 from a health care perspective and from dominance to US$PPP 874,562 from a societal
perspective. Across the studies showing a higher effectiveness in terms of additional DFD, col-
laborative care was associated with ICERs ranging from dominance to US$PPP 56.59 from a
health care perspective and from US$PPP 5.62 to 64.89 from a societal perspective.
Compared with incremental costs per additional QALY for collaborative care reported in
the review by van Steenbergen-Weijenburg et al. [18] (US$ 21,478 to 49,500), the current range
is considerably broader. All three studies with dominant ICERs used a health care perspective,
had a follow-up period of twelve to 24 months and were conducted in populations of depres-
sive patients with comorbid diseases or patients with post-surgery depression, respectively [38,
44, 51]. Yet, the study by Katon et al. [38] estimated QALYs based on a regression model and
the ICER showed a wide confidence interval. The ICER of the study by Pyne et al. [41] (US
$PPP 153,299), which exceeded the frequently applied cost-effectiveness threshold of US$
50,000 per additional QALY [53], resulted from high costs and modest effectiveness of collabo-
rative care. The ICER of the study by van der Weele et al. [47] (US$PPP 874,562 for patients
aged 75–80) resulted from a very small and non-significant effectiveness of collaborative care.
Across all studies included in this review, the time horizons of the economic evaluations as
well as the inclusion of indirect costs in the cost calculation varied considerably. Studies with
time horizons of more than one year had incremental costs per QALY gained ranging from
dominance to US$PPP 34,899, studies with time horizons of one year and below had incremen-
tal costs per QALY gained ranging from dominance to US$PPP 874,562. There might be a
trend showing better ICERs in studies with longer time horizons. Yet, ICERs may be influenced
not only by the time horizons but also by the intervention elements, the included cost elements
(e.g. inpatient costs, medication costs) and the size of health effects. In fact, the range of health
effect sizes in studies with time horizons of more than one year was 0.0173 to 0.335 incremental
QALYs, and in studies with time horizons one year and below it was −0.05 to 0.05 incremental
QALYs. According to the American Psychiatric Association [12], the average duration of
MDD is between 16 to 24 weeks. However, MDD is recurrent in around 40% of patients within
two years and unremitting in at least 15%, leading to persistent residual symptoms and social
or occupational impairment [12, 54, 55]. Around 5% to 10% of patients have a continuous
MDD for 2 or more years, illustrating the high risk of chronification [8]. Therefore, time hori-
zons of at least one to two years would be desirable, despite the high costs of clinical trials with
a long follow-up.
Only two included studies [33, 36] reported indirect costs of lost productivity, even though
eight studies used a societal perspective. However, none of those studies identified an effect of
depression treatment on indirect costs. This may be explained by the limited time horizon of
one year and by the inability to include presenteeism and unpaid work in the estimation of in-
direct costs [33, 36]. Yet, lost productivity has been reported to cause the largest share in total
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costs of patients with depression [7, 56, 57]. However, there is an ongoing debate on whether
to include indirect costs in economic evaluations [58, 59] and various national guidelines for
economic evaluations mainly recommend a health care payer’s perspective [60–63].
Methodological quality varied across studies. The range of scores on the 19-item CHEC-list
[28] was from eight to 17 points. Notably, the quality of the included studies improved over
time. Studies published before 2009 (47%) had a mean score of 12 points and studies published
after 2009 (53%) had mean score of 15 points. Seven studies reported neither significant incre-
mental effects nor significant incremental costs, possibly attributable to an insufficient sample
size [35, 36, 40, 47, 49–51]. Two studies themselves indicated that their cost-effectiveness anal-
yses were underpowered [35, 49], which is a common problem of economic evaluations con-
ducted alongside clinical trials [64–66]. In order to further improve quality of economic
evaluations it is suggested to conduct cost-effectiveness analyses based on samples large enough
to be confident in the resulting cost-effectiveness estimates [67], as it is anticipated in the study
embedded in the intersectoral research network “psychenet: Hamburg Network for Mental
Health (2011–2014)” [68].
The QALY valuation methods used across studies were mainly based on utility scales such
as EQ-5D or SF-6D. Two studies estimated QALYs based on regression models with DFD or
clinical measures as independent variables [38, 42]. According to Jonkers et al. [69] utility
scales should be preferred for cost-utility analyses to estimate health effects of quality improve-
ments for depression, compared with QALYs derived from DFD. Moreover, a direct compari-
son between those QALYs should be avoided [69].
It cannot be ruled out that cost-effectiveness analyses conducted alongside randomized con-
trolled trials of the effect of collaborative care for the treatment of depressive disorders in pri-
mary care remain unpublished [70]. Therefore, reporting bias may occur. Yet, it is beyond the
scope of this study to examine the retention of cost-effectiveness data to the public. However,
there appears to be a strong relationship between the strength and direction of effectiveness re-
sults and the presence of a concurrent economic evaluation [70], leading to a potential overesti-
mation of cost-effectiveness of collaborative care compared with usual care. In order to prevent
reporting bias, cost-effectiveness analyses should be guided by priorly published study proto-
cols [71].
Generalizability and comparability of the studies included in this review is debatable due to
methodological differences and heterogeneous general characteristics. Among others, the study
perspectives, settings and effect measures used varied significantly between the studies. For in-
stance, the differences in study perspectives may have led to differences in identification and
measurement of costs across studies, since, from a health care perspective, a more restricted se-
lection of cost elements is likely. The settings of the studies were mainly primary care clinics or
practices, yet in four different countries. Health care system characteristics across countries of
studies included in this review are expected to differ markedly. In addition, nearly half of all
studies only included female or elderly patients and patients with co-morbidities, respectively,
which are also factors potentially affecting generalizability [72]. In order to improve generaliz-
ability, PPP were used in this review to adjust for price level differences across countries [72,
73]. This approach clearly improved comparability across studies. However, it is still a gross
adjustment and not a reflection of differences in health care system, unit prices or care provider
characteristics between countries [72, 74].
Limitations of this study
This study has several limitations. First, not more than twelve of 19 studies reported either or
both significant differences in costs and effects between the collaborative care groups and usual
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care groups. Second, the cost-effectiveness of collaborative care compared with usual care was
potentially overestimated due to publication bias. Third, the heterogeneity of interventions
may have influenced the variation of ICERs as complexity and diversity of collaborative care el-
ements varied across studies. Fourth, the variation of cost categories included in the analyses
was considerable. Fifth, the majority of the studies were conducted in the USA. Generalizability
to health care systems outside the USA may be limited, because cost-effectiveness of collabora-
tive care may vary across populations and health insurance systems. Last, the review was limit-
ed to published studies in English or German, thus potentially introducing bias in the selection
of publications.
Conclusion
Despite our review improved the comparability of study results, cost-effectiveness of collabora-
tive care compared with usual care for the treatment of patients with depressive disorders in
primary care is ambiguous depending on willingness to pay for an additional QALY or DFD,
respectively. There remains considerable uncertainty due to inconsistent results among includ-
ed studies. Reviewed cost-effectiveness analyses differed considerably in terms of economic
quality, and risk of bias remained uncertain in the majority of studies, due to insufficient re-
porting. Future cost-effectiveness analyses using QALYs as summary measures and a time ho-
rizon of at least one year are needed in order to improve decision-making. Such studies should
be conducted in large and representative patient samples from a societal perspective, taking
into account indirect costs.
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